<DOC>
	<DOCNO>NCT02421211</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetic interaction simeprevir ledipasvir treatment regimen consist simeprevir ( SMV ) , sofosbuvir ( SOF ) , ledipasvir ( LDV ) treatment-naive participant chronic hepatitis C virus ( HCV ) genotype 1 infection .</brief_summary>
	<brief_title>A Study Investigate Pharmacokinetic Interactions Between Simeprevir Ledipasvir Treatment Regimen Consisting Simeprevir , Sofosbuvir , Ledipasvir Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , 2-panel , Phase 2 , randomize ( study medication assign participant chance ) study . The study consist 3 study phase : Screening Phase ( 5 week ) , Open-label Treatment Phase ( 70 day Panel 1 56 day Panel 2 ) , Post-treatment Follow-up Phase ( 12 week actual end treatment ) . Participants receive combination follow treatment : Treatment A : SMV 150 milligram ( mg ) daily ; Treatment B : LDV 90 mg along SOF 400 mg daily ; Treatment C : SOF 400 mg daily . Participants randomly assign Panel 1 ( Treatment AC follow Treatment AB ) Panel 2 ( Treatment B follow Treatment AB ) . The total study duration approximately 27 week participant Panel 1 25 week participant Panel 2 . Participants primarily access pharmacokinetic parameter . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Participants Body Mass Index ( weight kilogram [ kg ] divide square height meter ) 18.0 35.0 kilogram per square meter kg/m^2 , extremes included Participants must treatmentnaive ( , receive prior treatment approve investigational drug ) Participants HCV ribonucleic acid ( RNA ) plasma level great ( &gt; ) 10,000 international unit per milliliter ( IU/ml ) low 6,000,000 international unit per milliliter ( IU/ml ) screen Participants absence cirrhosis confirm FibroTest/Fibrosure score less equal 0.75 aspartate aminotransferase platelet ration index less equal 2 Fibroscan less equal 14.6 kilopascale ( kPA ) , perform within 6 month prior screen period Participants document chronic HCV infection : diagnosis HCV infection &gt; 6 month prior screen , either detectable HCV RNA , HCV positive antibody test presence histological change consistent chronic hepatitis liver biopsy Participant infection/coinfection HCV genotype genotype 1 , human immunodeficiency virus ( HIV ) type 1 2 Participant evidence liver disease nonHCV etiology . This include , limited acute hepatitis A , active hepatitis B , drug alcoholrelated liver disease , autoimmune hepatitis , hemochromatosis , Wilson 's disease , alpha1 antitrypsin deficiency , nonalcoholic steatohepatitis , primary biliary cirrhosis , nonHC liver disease consider clinically significant investigator Participant significant comorbidities , condition clinical significant finding screen assessment opinion investigator could compromise participant ' safety could interfere Participant participate complete study Participant receive organ transplant ( cornea hair transplant skin graft ) Participants key protocol define laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Simeprevir</keyword>
	<keyword>Ledipasvir</keyword>
	<keyword>Sofosbuvir</keyword>
</DOC>